Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great ChoiceZacks Investment Research • 10/20/25
Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a BetZacks Investment Research • 10/20/25
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal AdenocarcinomaBusiness Wire • 10/19/25
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung CancerBusiness Wire • 08/13/25
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 08/07/25
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to DeclineZacks Investment Research • 07/31/25
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025Business Wire • 07/29/25
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic CancerBusiness Wire • 07/24/25
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical OncologyBusiness Wire • 07/11/25
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian CancerBusiness Wire • 06/30/25
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid TumorsBusiness Wire • 06/24/25
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorBusiness Wire • 06/02/25
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug ApprovalZacks Investment Research • 05/28/25
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal AdenocarcinomaBusiness Wire • 05/22/25
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination TreatmentBusiness Wire • 05/20/25
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 05/13/25
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 05/08/25